Methods for treatment of inflammatory diseases
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/415
A61K-009/13
A61K-009/107
출원번호
US-0758696
(2001-01-11)
발명자
/ 주소
Farber, Elliott
출원인 / 주소
Alwyn Company, Inc.
대리인 / 주소
Hogan & Hartson LLP
인용정보
피인용 횟수 :
6인용 특허 :
58
초록▼
An improved method of treating skin diseases comprises applying to the skin of a patient suffering such a skin disease an allantoin-containing composition in a therapeutically effective quantity. The allantoin-containing composition is a water-in-oil emulsion that includes allantoin and an emulsifie
An improved method of treating skin diseases comprises applying to the skin of a patient suffering such a skin disease an allantoin-containing composition in a therapeutically effective quantity. The allantoin-containing composition is a water-in-oil emulsion that includes allantoin and an emulsifier system that includes at least one emulsifier that is either an anionic emulsifier or a nonionic emulsifier. If the emulsifier is an anionic emulsifier, the emulsifier system can include beeswax. The nonionic emulsifiers used can include at least one nonionic emulsifier that is an ethoxylated ether or an ethoxylated ester whose carbon chain length ranges from 8 to 22 carbon atoms. Alternatively, the emulsifier system can include an acidic anionic polymer such as carboxypolymethylene and an anionic emulsifier. In another alternative, the emulsifier system can include the acidic anionic polymer and a nonionic emulsifier, or the acidic anionic polymer alone. In still another alternative, the emulsifier system can include cetyl alcohol and stearic acid. In yet another alternative, the emulsifier system can include sodium stearoyl lactylate and sodium isostearoyl lactylate. In another alternative, the emulsifier system can include at least one polyethyleneglycol ether of cetearyl alcohol. In still another alternative, the emulsifier system can include a polyethylene glycol ester of stearic acid and glyceryl stearate. The composition can include other ingredients. The pH of the composition used in a method according to the present invention is from about 3.0 to about 6.0; preferably, a narrower pH range is used, varying with each embodiment of the composition. Among the diseases that can be treated is epidermolysis bullosa.
대표청구항▼
An improved method of treating skin diseases comprises applying to the skin of a patient suffering such a skin disease an allantoin-containing composition in a therapeutically effective quantity. The allantoin-containing composition is a water-in-oil emulsion that includes allantoin and an emulsifie
An improved method of treating skin diseases comprises applying to the skin of a patient suffering such a skin disease an allantoin-containing composition in a therapeutically effective quantity. The allantoin-containing composition is a water-in-oil emulsion that includes allantoin and an emulsifier system that includes at least one emulsifier that is either an anionic emulsifier or a nonionic emulsifier. If the emulsifier is an anionic emulsifier, the emulsifier system can include beeswax. The nonionic emulsifiers used can include at least one nonionic emulsifier that is an ethoxylated ether or an ethoxylated ester whose carbon chain length ranges from 8 to 22 carbon atoms. Alternatively, the emulsifier system can include an acidic anionic polymer such as carboxypolymethylene and an anionic emulsifier. In another alternative, the emulsifier system can include the acidic anionic polymer and a nonionic emulsifier, or the acidic anionic polymer alone. In still another alternative, the emulsifier system can include cetyl alcohol and stearic acid. In yet another alternative, the emulsifier system can include sodium stearoyl lactylate and sodium isostearoyl lactylate. In another alternative, the emulsifier system can include at least one polyethyleneglycol ether of cetearyl alcohol. In still another alternative, the emulsifier system can include a polyethylene glycol ester of stearic acid and glyceryl stearate. The composition can include other ingredients. The pH of the composition used in a method according to the present invention is from about 3.0 to about 6.0; preferably, a narrower pH range is used, varying with each embodiment of the composition. Among the diseases that can be treated is epidermolysis bullosa. c micelles," Gene Ther. 8:999-1004, Nature Publishing Group (Jul. 2001). Lin, H., et al., "Expression of Recombinant Genes in Myocardium In Vivo After Direct Injection of DNA," Circulation 82:2217-2221, Lippincott Williams and Wilkins (Dec. 1990). Liptay, S., et al., "Colon Epithelium Can Be Transiently Transfected with Liposomes, Calcium Phosphate Precipitation and DEAE Dextran in vivo," Digestion 59:142-147, S. Karger AG (Mar. 1998). Lopata, M.A., et al., "High level transient expression of a chloramphenicol acetyl transferase gene by DEAE-dextran mediated DNA transfection coupled with a dimethyl sulfoxide or glycerol shock treatment," Nucl. Acids. Res. 12:5707-5717, IRL Press Ltd. (1984). Luo, D., et al., "Controlled DNA Delivery Systems," Parm. Res. 16:1300-1308, Plenum Publishing Corp. (Aug. 1999). Luo, D. and Saltzman, W.M., "Synthetic DNA delivery systems," Nat. Biotechnol. 18:33-37, Nature Publishing Co. (Jan. 2000). MacLaughlin, F.C., et al., "Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery," J. Control. Release 56:259-272, Elsevier Science (Dec. 1998). Manthorpe, M., et al., "Gene Therapy by Intramuscular Injection of Plasmid DNA: Studies on Firefly Luciferase Gene Expression in Mice," Hum. Gene Ther. 4:419-431, Mary Ann Liebert, Inc. (Aug. 1993). Mao, H.-Q., et al., "Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency," J. Control. Release 70:399-421, Elsevier Science (Feb. 2001). Martin, T., et al., "Plasmid DNA Malaria Vaccine: The Potential for Genomic Integration after Intramuscular Injection," Hum. Gene Ther. 10:759-768, Mary Ann Liebert, Inc. (Mar. 1999). Mumper, R.J., et al., "Polyvinyl Derivatives as Novel Interactive Polymers for Controlled Gene Delivery to Muscle," Pharm. Res. 13:701-709, Plenum Publishing Corp. (May 1996). Mumper, R.J., et al., "Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle," J. Control. Release 52: 191-203, Elsevier Science (Mar. 1998). Pachuk, C.J., et al., "Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine," Biochim. Biophys. Acta 1468:20-30, Elsevier Science (Sep. 2000). Prevec, L., et al., "Use of Human Adenovirus-based Vectors for Antigen Expression in Animals," J. Gen. Virol. 70:429-434, Society for General Microbiology (Feb. 1989). Roy, K., et al., "Oral gene delivery with chitosan-DNA nanoparticles generated immunologic protection in a murine model of peanut allery," Nat. Med. 5:387-391, Macmillan Magazines Ltd. (Apr. 1999). Sanford, J.C., et al., "Delivery of Substances into Cells and Tissues Using a Particle Bombardment Process," Partic. Sci. Tech. 5:27-37, Hemisphere Publishing Corp. (1987). Sompayrac, L.M. and Danna, K.J., "Efficient infection of monkey cells with DNA of simian virus 40," Proc. Natl. Acad. Sci. USA 78:7575-7578, National Academy of Sciences (1981). Sureau, C., et al., "Clone Hepatitis Delta Virus cDNA Is Infectious in the Chimpanzee," J. Virol. 63:4292-4297, American Society for Microbiology (Oct. 1989). Tang, D.-C., et al., "Genetic immunization is a simple method for eliciting an immune response," Nature 356:152-154, Macmillan Magazines Ltd. (Mar. 1992). Venneman, M.R., "Immunogenicity of Ribonucleic Acid Preparations Obtained from Salmonella typhimurium," Infect. Immun. 1:574-582, American Society for Microbiology (1970). Wang, D., et al., "Encapsulation of plasmid DNA in biodegradable poly(D.L-Lactic-co
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (58)
Lanzendorfer Ghita,DEX ; Stab Franz,DEX ; Untiedt Sven,DEX, Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides.
Phalangas Charalambos J. (Wilmington DE), Allantoin salts of quaternary nitrogen containing polymers for use in skin conditioning, cosmetic and pharmaceutical for.
Alliger Howard (10 Ponderosa Dr. Melville NY 11747) Roozdar Habib (9 Rolling Hills Dr. Nesconset NY 11767), Chlorine dioxide skin medicating compositions for preventing irritation.
Puchalski Eugene (Jersey City NJ) Donahue Frances A. (Middletown NJ) Dixon Richard P. (Aberdeen NJ), Combined allantoin-hydrolyzed animal protein product and method.
Goode Stephen T. (Woodstock IL) Linton Robert R. (Crystal Lake IL) Baiocchi Fred (Prairie Village KS), Cosmetic base composition with therapeutic properties.
Grollier Jean-Francois (Paris FRX) Allec Josiane (Pierrefitte FRX) Fourcadier Chantal (Paris FRX) Rosenbaum Georges (Asnieres FRX) Darmenton Patrick (Villejuif FRX), Cosmetic composition for the treatment of the hair and skin comprising a powder of flowers or flower tops and a cohesion.
Grollier Jean-Francois (Paris FRX) Allec Josiane (Pierrefitte FRX) Fourcadier Chantal (Paris FRX) Rosenbaum Georges (Asnieres FRX) Darmenton Patrick (Villejuif FRX), Cosmetic compositions for the treatment of the hair and skin contain in the form of a powder particles resulting from th.
Grollier Jean-Francois (Paris FRX) Allec Josiane (Pierrefitte FRX) Fourcadier Chantal (Paris FRX) Rosenbaum Georges (Asnieres FRX) Darmenton Patrick (Villejuif FRX), Cosmetic compositions for the treatment of the hair and skin contain in the form of a powder particles resulting from th.
Deckner George Endel ; Rinaldi Marie Antoinette ; Szymanski Victoria Claire, Low PH, hydrolytically stable, cosmetic compositions containing acidic actives.
Garlen David (Roselle Park NJ) Koehn Hilde R. (Huntington NY) Koehn Peter W. (Huntington NY) McColl J. D. (Chattanooga TN), Mature skin treatment and protectant compositions and methods of using same.
France James R. (Overland Park KS) Baiocchi Fred (Prairie Village KS) Concar George A. (Bloomingdale IL), Stable water in oil emulsion systems for cosmetic and pharmaceutical preparations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.